Cantor Fitzgerald Comments on ZVRA FY2026 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Zevra Therapeutics in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings of $0.98 per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price target on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $20.40 million for the quarter, compared to the consensus estimate of $16.96 million. During the same period in the previous year, the firm posted ($0.40) earnings per share.

ZVRA has been the subject of several other reports. Guggenheim boosted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen raised shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $22.29.

Zevra Therapeutics Stock Down 2.6%

ZVRA stock traded down $0.24 during trading hours on Wednesday, hitting $9.13. The company's stock had a trading volume of 533,628 shares, compared to its average volume of 668,305. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $499.23 million, a PE ratio of -4.63 and a beta of 2.01. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The stock has a 50 day moving average price of $7.97 and a two-hundred day moving average price of $8.07.

Insider Transactions at Zevra Therapeutics

In related news, Director John B. Bode bought 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The stock was purchased at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the purchase, the director now directly owns 40,000 shares in the company, valued at $318,400. This trade represents a 33.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Several large investors have recently bought and sold shares of ZVRA. Rhumbline Advisers raised its stake in shares of Zevra Therapeutics by 9.6% in the 1st quarter. Rhumbline Advisers now owns 74,585 shares of the company's stock valued at $559,000 after buying an additional 6,532 shares in the last quarter. Strs Ohio acquired a new position in shares of Zevra Therapeutics in the 1st quarter valued at $125,000. Woodline Partners LP raised its stake in shares of Zevra Therapeutics by 11.5% in the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock valued at $34,571,000 after buying an additional 476,032 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock valued at $238,000 after buying an additional 1,812 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. raised its stake in shares of Zevra Therapeutics by 6.9% in the 1st quarter. Retirement Planning Co of New England Inc. now owns 550,180 shares of the company's stock valued at $4,121,000 after buying an additional 35,348 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.